News
BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...
German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...
BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...
InvestorsHub on MSN6d
BioNTech shares climb over 2% as Q2 revenue doubles, Bristol Myers partnership boosts outlookBioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...
“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...
Stocktwits on MSN5d
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline PushBioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on ...
BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...
BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.
The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback